<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001504</url>
  </required_header>
  <id_info>
    <org_study_id>VIP-ACS trial</org_study_id>
    <nct_id>NCT04001504</nct_id>
  </id_info>
  <brief_title>Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes</brief_title>
  <acronym>VIP-ACS</acronym>
  <official_title>Evaluation of the Effectiveness of Double Dose Influenza Vaccination to Reduce Major Cardiovascular Events After an Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease has a great burden in the context of public health, as well as the low&#xD;
      pharmacological adherence of patients who have chronic non-transmissible diseases. However,&#xD;
      the investigators do not have data on the efficiency of vaccination to reduce cardiovascular&#xD;
      events in the acute coronary syndromes, and the few studies evaluating the cardioprotective&#xD;
      potential of the influenza vaccine were conducted in countries with well defined&#xD;
      seasonalities, divergent of Brazil, that presents a constant viral circulation during all&#xD;
      months of the year and distinct among its regions. Therefore, study evaluating higher dose&#xD;
      vaccination in a period that contemplates the seasonality of the influenza virus in Brazil&#xD;
      may bring important findings to different scientific gaps, as well as clarify questions about&#xD;
      the possible benefit of doubled vaccination - which does not present contraindications -&#xD;
      immediately after a atherothrombotic event. If it shows real benefit, it could also be a&#xD;
      future therapeutic tool adjuvant to traditional drug therapy in the prevention of&#xD;
      cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, randomized, controlled, multicenter, open-label, superiority, 1:1 allocation,&#xD;
      blind assessment of clinical outcomes and intention-to-treat analysis clinical trial to&#xD;
      determine whether increased doses(double dose) of influenza vaccine in the hospital phase,&#xD;
      when compared to usual dose vaccination (30 days of randomization), decreases the risk of&#xD;
      cardiovascular and respiratory events. Hospitalizations due to COVID-19 are excluded from the&#xD;
      respiratory infection component of the primary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hierarchical composite endpoint consisting of death, myocardial infarction, stroke, unstable angina hospitalization, heart failure hospitalization, urgent coronary revascularization or respiratory infections hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective will be analyzed using the win ratio approach comparing every participant of treatment group to every participant of control group to determine a winner</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key Secondary End Point is a hierarchical outcome consisting only of cardiovascular death, myocardial infarction or stroke.</measure>
    <time_frame>12 months</time_frame>
    <description>The key secondary end point will be analyzed using the win ratio approach comparing every participant of treatment group to every participant of control group to determine a winner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Time to first occurrence of first mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unstable angina hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of Unstable angina hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of Heart failure hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory infections hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of hospitalization due to upper and lower respiratory tract infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent coronary revascularization ischemia guide</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of urgent coronary revascularization ischemia guide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of probable and definite stent thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury</measure>
    <time_frame>12 months</time_frame>
    <description>Acute myocardial infarction defined by forth universal definition24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 hospitalizations and infections</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of COVID-19 hospitalizations and infections</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Solicited injection site and systemic events, unsolicited adverse events and serious adverse events following vaccination.</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Occurrence of solicited injection site (Pain, Erythema, Swelling, Induration, and Bruising) and systemic reactions (Fever, Headache, Malaise, Myalgia, and Shivering) will be assessed in all participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety overview after influenza vaccination until the end of the study.</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of unsolicited adverse events, including serious adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Double Dose Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double Dose QIV during index ACS hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Dose QIV 30 days after randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Double Dose Quadrivalent Influenza Vaccine</intervention_name>
    <description>Double Dose QIV (30µg Hemagglutinin)</description>
    <arm_group_label>Double Dose Quadrivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard Dose Quadrivalent Influenza Vaccine</intervention_name>
    <description>Standard Dose QIV (15µg Hemagglutinin)</description>
    <arm_group_label>Standard Dose Quadrivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age &gt;= 18 years and older&#xD;
&#xD;
          -  Acute coronary syndrome in hospital phase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical trial with vaccines;&#xD;
&#xD;
          -  Refusal to provide consent;&#xD;
&#xD;
          -  Hypersensitivity and/or anaphylaxis to any component of the vaccine, or Guillain-Barré&#xD;
             within 6 weeks after previous influenza vaccine;&#xD;
&#xD;
          -  Have already received the influenza vaccine with the same strains used in the study&#xD;
             within the last 12 months of inclusion in the study&#xD;
&#xD;
          -  Breastfeeding women;&#xD;
&#xD;
          -  Pregnant women;&#xD;
&#xD;
          -  Presenting an acute coronary syndrome during months of December, January, and&#xD;
             February.&#xD;
&#xD;
          -  Acute coronary syndrome hospitalization &gt;7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otávio Berwanger, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academic Research Organization -- Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrique A Fonseca, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Research Organization -- Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrique A Fonseca, PhD</last_name>
    <phone>55+ 11 21513725</phone>
    <email>henrique.fonseca@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Remo Furtado, PhD</last_name>
    <email>remo.furtado@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital e Clínica São Roque</name>
      <address>
        <city>Ipiaú</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Vieira, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Daniel Vicente</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Ana Nery</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz C Passos, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Daniela Dorta</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Cárdio Pulmonar</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Ritt, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Queila Borges</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Ceará / Hospital Universitário Walter Cantídio</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Pereira, MD-PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Maria Marinho</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Distrito Federal</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenzo Fernandes</last_name>
    </contact>
    <investigator>
      <last_name>Diego M Mesquita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Lucia</name>
      <address>
        <city>Poços De Caldas</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gislayne Ribeiro</last_name>
    </contact>
    <investigator>
      <last_name>Frederico TC Dall'Orto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Bergo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Ciências Médicas</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brumo Ramos, MD-PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Carlos Areas, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario da Universidade Estadual de Londrina</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manoel Canesin, MD-PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Fabio Sekiama</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Agamenon Magalhães</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João BM Xavier, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Shila Ribeiro</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pronto Socorro Cardiológico de Pernambuco</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarcya Patriota, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Rodrigo P Pedrosa, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo L Patriota, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulo Caramori, MD-PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Denise Pellegrini</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual de Cardiologia Aloysio de Castro</name>
      <address>
        <city>Rio De Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone R Souza</last_name>
    </contact>
    <investigator>
      <last_name>Aline S Villacorta, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauren P Haeffner</last_name>
    </contact>
    <contact_backup>
      <last_name>Angelica Zanotto</last_name>
    </contact_backup>
    <investigator>
      <last_name>Carisi A Polanczyk, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariana V Vargas, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IPEMI - Instituto de Pesquisas Médicas de Itajaí</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Baldissera, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sidney Lourenço</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Dona Helena</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Penha, MD-PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Michele Coral</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Hans Dieter Schmidt</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conrado Hoffmann, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Carla Hoffmann</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clinica do Coração</name>
      <address>
        <city>Aracaju</city>
        <state>Sergipe</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Serra, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marcos Serra Silveira, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina de Botucatu - UNESP</name>
      <address>
        <city>Botucatu</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A Vieira</last_name>
    </contact>
    <contact_backup>
      <last_name>Nelmara Camargo</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marina P Okoshi, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Marília</name>
      <address>
        <city>Marília</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robson Alves</last_name>
    </contact>
    <investigator>
      <last_name>Pedro B Andrade, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração - HC FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natassja Huemer</last_name>
    </contact>
    <contact_backup>
      <last_name>Alexandra Vieira</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jose C Nicolau, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa M Baldo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Talia F Dalçoquio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Presidente Prudente</name>
      <address>
        <city>Presidente Prudente</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Bosso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Ramos, MD-PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Renata Viana, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unstable angina</keyword>
  <keyword>Non-ST-Elevation Myocardial Infarction - NSTEMI</keyword>
  <keyword>ST-Elevation Myocardial Infarction - STEMI</keyword>
  <keyword>Quadrivalent Influenza Vaccine - QIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

